Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.
Gagliardini R, Lorenzini P, Cozzi-Lepri A, Tavelli A, Borghi V, Galli L, Tagliaferri G, Maggiolo F, Mussini C, Castagna A, Monforte AD, Antinori A. Gagliardini R, et al. Among authors: maggiolo f. J Glob Antimicrob Resist. 2023 Mar;32:158-163. doi: 10.1016/j.jgar.2022.11.010. Epub 2022 Nov 17. J Glob Antimicrob Resist. 2023. PMID: 36402369 Free article.
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).
Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V. Carosi G, et al. Among authors: maggiolo f. J Antimicrob Chemother. 2006 Jun;57(6):1055-64. doi: 10.1093/jac/dkl113. Epub 2006 Apr 10. J Antimicrob Chemother. 2006. PMID: 16606637
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: maggiolo f. J Antimicrob Chemother. 2007 Jun;59(6):1141-7. doi: 10.1093/jac/dkm100. Epub 2007 Apr 13. J Antimicrob Chemother. 2007. PMID: 17434879
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group. d'Arminio Monforte A, et al. Among authors: maggiolo f. Clin Infect Dis. 2009 Aug 15;49(4):612-22. doi: 10.1086/603557. Clin Infect Dis. 2009. PMID: 19591597
337 results